Proceedings of the Ninth International Conference of Drug Regulatory Authorities (ICDRA) - Berlin, Germany 25-29 April 1999
(1999; 102 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoOpening Ceremony
Abrir esta carpeta y ver su contenidoGood regulatory practice
Abrir esta carpeta y ver su contenidoGood certification practice
Abrir esta carpeta y ver su contenidoCounterfeit drugs: challenges and solutions
Abrir esta carpeta y ver su contenidoCurrent issues in regulation and quality
Abrir esta carpeta y ver su contenidoInternational Conference on Harmonization: implementation and implications
Abrir esta carpeta y ver su contenidoDrug utilization studies
Abrir esta carpeta y ver su contenidoInternational Conference on Harmonization and the common technical document
Abrir esta carpeta y ver su contenidoKeynote address
Abrir esta carpeta y ver su contenidoGlobal and national efforts to reduce tobacco use
Abrir esta carpeta y ver su contenidoElectronic communication in the regulatory process
Abrir esta carpeta y ver su contenidoTransparency in monitoring the safety of medicines
Abrir esta carpeta y ver su contenidoPharmaceutical products for use in special groups
Abrir esta carpeta y ver su contenidoNeed for Bioequivalence
Abrir esta carpeta y ver su contenidoAntimicrobial resistance: battling the bugs
Abrir esta carpeta y ver su contenidoSafety issues of plasma-derived medicinal products
Cerrar esta carpetaHerbal medicines
Ver el documentoRegulation of traditional Chinese medicines
Ver el documentoRegulation of herbal medicines in the European Union
Ver el documentoGuidelines for evaluating herbal medicines
Ver el documentoRegulation of complementary medicines
Ver el documentoRecommendations
Abrir esta carpeta y ver su contenidoRegulation and access to essential drugs
Ver el documentoParticipants
Ver el documentoBack cover
 

Recommendations

1. Member States should formulate national policies on traditional medicines taking into particular consideration the traditional processing of herbal preparations and raw materials within local communities. Emphasis should be placed on the development or updating of national legislation for registration and licensing of industrially-prepared herbal medicines, as well as for the regulation of traditional medical practice as an integral component of the national health system.

2. WHO should continue to co-operate with governmental institutions in developing and updating guidelines on the assessment of the quality, safety and efficacy of herbal medicines.

3. WHO should update quality control methods for medicinal materials including the introduction of new technical methods, e.g. capillary electrophoresis to replace solvent extraction and solvent-mixture TLC or HPLC techniques.

4. WHO should continue to compile knowledge on the safety and efficacy of herbal medicines, including development of WHO monographs on selected medicinal plants.

5. WHO should consult on a definition for the terms “traditional” or “herbal” medicine and “drugs” and how these should be delineated from the terms “food” and “dietary supplements”.

6. WHO should collaborate with Member States to strengthen the safety monitoring of herbal medicines.

7. WHO and Regional Offices should work together to organise training courses for national authorities and traditional medicine practitioners on assuring the quality, safety and efficacy of herbal medicines.

8. WHO should continue to disseminate information and assure fast and wide availability of all relevant documents via electronic media and the internet.

9. WHO should continue to prepare similar guidelines in related fields of traditional medicine, especially on the quality and safety of homoeopathic products.

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013